Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2315-2322

  Miranda Zapico, Ilargi ^a   Eraso, Elena ^a   Hernández Almaraz, José Luis ^b   López Soria, Leyre Mónica ^b   Carrillo Muñoz, Alfonso Javier ^c   Hernández Molina, Juan Manuel ^d   Quindós, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c Associacio Catalana d'Intelligencia Artificial   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Antifungal susceptibility; C. bracarensis; C. glabrata; C. metapsilosis; C. nivariensis; C. orthopsilosis; C. parapsilosis; Spain

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; CANDIDA GLABRATA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; FUNGUS CULTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN;

ANTIFUNGAL AGENTS; BLOOD; CANDIDA; CANDIDA GLABRATA; CANDIDEMIA; DRUG RESISTANCE, MULTIPLE, FUNGAL; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; SPAIN;

EID: 80052892188     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr298     Document Type: Article

References (36)

1. Gomez J, Garcia-Vazquez E, Espinosa C et al. Nosocomial candidemia at a general hospital: the change of epidemiological and clinical characteristics. A comparative study of 2 cohorts (1993-1998 versus 2002-2005). Rev Iberoam Micol 2009; 26: 184-8.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
3. Moran C, Grussemeyer CA, Spalding JR et al. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J 2009; 28: 433-5.
4. Correia A, Sampaio P, James S et al. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol 2006; 56: 313-7
5. Alcoba-Fló rez J, Méndez-Á lvarez S, Cano J et al. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005; 43: 4107-11.
6. Borman AM, Petch R, Linton CJ et al. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008; 46: 933-8.
7. Cassone A, De BF, Pontieri E et al. Biotype diversity of Candida parapsilosis and its relationship to the clinical source and experimental pathogenicity. J Infect Dis 1995; 171: 967-75.
8. Lockhart SR, Messer SA, Pfaller MA et al. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-64.
9. de Toro M, Torres MJ, Maite R et al. Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect 2011; 17: 418-24.
10. Gómez-López A, Alastruey-Izquierdo A, Rodri{dotless}́guez D et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-9.
11. Moudgal V, Little T, Boikov D et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-9.
12. Cantón E, Espinel-Ingroff A, Pemán J et al. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis by time-kill studies. Antimicrob Agents Chemother 2010; 54: 2194-7.
13. Eraso E, Moragues MD, Villar-Vidal M et al. Evaluation of the new chromogenic medium Candida ID 2 for isolation and identification of Candida albicans and other medically important Candida species. J Clin Microbiol 2006; 44: 3340-5.
14. Romeo O, Scordino F, Pernice I et al. A multiplex PCR protocol for rapid identification of Candida glabrata and its phylogenetically related species Candida nivariensis and Candida bracarensis. J Microbiol Methods 2009; 79: 117-20.
15. Tavanti A, Davidson AD, Gow NA et al. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-92.
16. White PL, Shetty A, Barnes RA. Detection of seven Candida species using the Light-Cycler system. J Med Microbiol 2003; 52: 229-38.
17. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Third Informational Supplement M27-S3. CLSI, Wayne, PA, USA, 2008.
18. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-76.
19. Pfaller MA, Andes D, Diekema DJ et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-95.
20. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-43.
21. Quindós G, Sánchez-Vargas LO, Villar-Vidal M et al. Activities of fluconazole and voriconazole against bloodstream isolates of Candidaglabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. Int J Antimicrob Agents 2008; 31: 266-71.
22. Lockhart SR, Messer SA, Gherna M et al. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol 2009; 47: 1216-7.
23. Orsi CF, Colombari B, Blasi E. Candida metapsilosis as the least virulent member of the 'C. parapsilosis' complex. Med Mycol 2010; 48: 1024-33.
24. Tavanti A, Hensgens LA, Ghelardi E et al. Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45: 1455-62.
25. Chen YC, Lin YH, Chen KW et al. Molecular epidemiology and antifungal susceptibility of Candida parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis in Taiwan. Diagn Microbiol Infect Dis 2010; 68: 284-92.
26. Asadzadeh M, Ahmad S, Al-Sweih N et al. Rapid molecular differentiation and genotypic heterogeneity among Candida parapsilosis and Candida orthopsilosis strains isolated from clinical specimens in Kuwait. J Med Microbiol 2009; 58: 745-52.
27. Tay ST, Na SL, Chong J. Molecular differentiation and antifungal susceptibilities of Candida parapsilosis isolated from patients with bloodstream infections. J Med Microbiol 2009; 58: 185-91.
28. Kocsubé S, Tóth M, Vagvö lgyi C et al. Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol 2007; 56: 190-5.
29. Garcia-Effron G, Katiyar SK, Park S et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reducedechinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-12.
30. Quindós G, Ruesga MT, Marti{dotless}́n-Mazuelos E et al. In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol 2004; 21: 63-9.
31. Gonçalves SS, Amorim CS, Nucci M et al. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin Microbiol Infect 2010; 16: 885-7.
32. Pryce TM, Palladino S, Price DM et al. Rapid identification of fungal pathogens in BacT/ALERT, BACTEC, and BBL MGIT media using polymerase chain reaction and DNA sequencing of the internal transcribed spacer regions. Diagn Microbiol Infect Dis 2006; 54: 289-97.
33. Silva AP, Miranda IM, Lisboa C et al. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009; 47: 2392-7.
34. Mirhendi H, Bruun B, Schonheyder HC et al. Molecular screening for Candida orthopsilosis and Candida metapsilosis among Danish Candida parapsilosis group blood culture isolates: proposal of a new RFLP profile for differentiation. J Med Microbiol 2010; 59: 414-20.
35. Paugam A, Baixench MT, Taieb F et al. [Emergence of Candida parapsilosis candidemia at Cochin hospital. Characterization of isolates and search for risk factors]. Pathol Biol (Paris) 2011; 59: 44-7.
36. Thierry G, Morio F, Le PP et al. [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-testw]. Pathol Biol (Paris) 2011; 59: 52-6.